IRRA Stock Overview
Trades in laboratory and pharmaceutical equipment, and medical devices in Indonesia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PT Itama Ranoraya Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp444.00 |
| 52 Week High | Rp1,045.00 |
| 52 Week Low | Rp436.00 |
| Beta | 0.89 |
| 11 Month Change | -6.33% |
| 3 Month Change | -2.20% |
| 1 Year Change | -6.33% |
| 33 Year Change | -74.34% |
| 5 Year Change | -11.20% |
| Change since IPO | -20.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| IRRA | ID Healthcare | ID Market | |
|---|---|---|---|
| 7D | -3.5% | -1.7% | -2.4% |
| 1Y | -6.3% | 24.0% | 12.2% |
Return vs Industry: IRRA underperformed the ID Healthcare industry which returned 24% over the past year.
Return vs Market: IRRA underperformed the ID Market which returned 12.2% over the past year.
Price Volatility
| IRRA volatility | |
|---|---|
| IRRA Average Weekly Movement | 5.0% |
| Healthcare Industry Average Movement | 5.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in ID Market | 12.8% |
| 10% least volatile stocks in ID Market | 2.4% |
Stable Share Price: IRRA has not had significant price volatility in the past 3 months compared to the ID market.
Volatility Over Time: IRRA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 229 | Heru Syarif | www.itama.co.id |
PT Itama Ranoraya Tbk trades in laboratory and pharmaceutical equipment, and medical devices in Indonesia. The company offers in vitro diagnostics products comprising rapid test and clinical laboratory; imaging products, including ultrasound, bone densitometer, C-arm, flat panel digital detector, mobile and stationary x-ray, and mammography; cardiovascular, urology, and surgical products; and hospital supplies. It also provides cold chain management, such as cold room and vaccine, bloodbank, and pharmaceutical refrigerator; critical care; and pharmaceutical supplements, as well as maternal and neonatal care products.
PT Itama Ranoraya Tbk Fundamentals Summary
| IRRA fundamental statistics | |
|---|---|
| Market cap | Rp669.47b |
| Earnings (TTM) | Rp10.00b |
| Revenue (TTM) | Rp974.77b |
67.0x
P/E Ratio0.7x
P/S RatioIs IRRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRRA income statement (TTM) | |
|---|---|
| Revenue | Rp974.77b |
| Cost of Revenue | Rp794.88b |
| Gross Profit | Rp179.89b |
| Other Expenses | Rp169.90b |
| Earnings | Rp10.00b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.63 |
| Gross Margin | 18.45% |
| Net Profit Margin | 1.03% |
| Debt/Equity Ratio | 64.6% |
How did IRRA perform over the long term?
See historical performance and comparison